| Project/Area Number |
17390449
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
KYO Satoru Kanazawa University, Graduate School Of Medical Science, Associate Prof. (50272969)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
INOUE Masaki Kanazawa University, Graduate School Of Medical Science, Prof (10127186)
中村 充宏 金沢大学, 医学部附属病院, 助手 (50377397)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥16,320,000 (Direct Cost: ¥15,300,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2007: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2006: ¥5,000,000 (Direct Cost: ¥5,000,000)
Fiscal Year 2005: ¥6,900,000 (Direct Cost: ¥6,900,000)
|
|---|
| Keywords | Virotheranv / Replication-competent adenovirus / hTERT nromntnr / telomerase / hTERT / adenovirus / gene therapy |
|---|
| Research Abstract |
We previously cloned the promoter of human reverse transcriptase (hTERT) gene, a catalytic subunit of human telomerase, which was found to be active only in cancer cells with telomerase activity, while it was silent in most normal cells without telomerase activity. We have planned to insert this promoter into the upstream of the El gene of Adenovirus type 5 genome so that adenovirus El gene is efficiently expressed only in cancer cells. Eventually, this chimera virus can replicate only in cancer cells with high levels of expression of El gene, which is required for viral replication. We named this virus TRAD: telomerase-specific replication adenovirus. In the present project, we examined the in vitro and in vivo efficacy of TARD directly injected into primary site of tumors. We found that TARD was effective to reduce tumor burden without exhibiting any severe adverse effect, such as myelosurpression or liver dysfunction caused by viral toxicity Therefore, we propose the clinical use of this virus.
|
